Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 4, Michael Ulz of Morgan Stanley reiterated a Buy rating on Dyne Therapeutics, Inc. (NASDAQ:DYN) with a price target of $48.

The analyst noted that the FDA granted Breakthrough Therapy Designation to the company’s DYNE-251. He noted that this indicates a strong need for new treatments of Duchenne muscular dystrophy. DYNE-251 targets patients who are eligible for exon 51 skipping, which is a specific genetic approach.

Moreover, the treatment has been showing promising early clinical results, and the designation by the FDA will allow the company to move faster in development and regulatory reviews.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage company focused on developing treatments for genetically driven neuromuscular diseases.

While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.